FAM20C Genotype

If you or a partner has a family history of severe bone or dental abnormalities, brain calcifications, or unexplained phosphate problems passed across generations, the FAM20C gene is one of the small set of places where a single inherited change can explain everything. This test reads the gene that builds an enzyme central to how your body mineralizes bone and teeth.

FAM20C (family with sequence similarity 20, member C) sits at the top of a pathway that affects bone hardness, tooth structure, and how your kidneys handle phosphate. A loss-of-function change in this gene causes Raine syndrome, a rare condition that ranges from severe disease in infancy to milder bone and dental problems that surface later in life.

What FAM20C Actually Does

The FAM20C gene contains the instructions for an enzyme called a protein kinase, which is a type of enzyme that adds a chemical tag (a phosphate group) onto other proteins to change how they behave. This enzyme works inside the Golgi apparatus, a structure inside your cells that processes proteins before they are sent out into the bloodstream and tissues. FAM20C tags more than 100 different proteins with phosphate, generating most of the proteins your body sends out that carry this kind of chemical marker.

The enzyme is most active in tissues that have to harden: bone, dentin, and tooth enamel. Its targets include a family of proteins that build mineral structure in bone and teeth, and a hormone called FGF23 (fibroblast growth factor 23), which tells your kidneys how much phosphate to keep or release. When FAM20C works properly, bones and teeth mineralize normally and phosphate stays in balance.

Raine Syndrome

Inheriting two damaging copies of FAM20C, one from each parent, causes Raine syndrome. The condition spans a wide spectrum. The severe form appears at birth with dense bone abnormalities, facial differences, and calcium deposits in the brain. Milder forms can show up later in childhood or even adulthood, with softer bones, dental anomalies, and low phosphate levels.

A study of two patients with FAM20C mutations documented a pattern of dysregulated FGF23 levels, low blood phosphate, excess phosphate loss in urine, dental anomalies, brain calcifications, and dense bone, all without the classic rickets pattern typically seen in childhood bone disease. Twelve children followed in a separate natural-history study showed respiratory distress, neurodevelopmental delays, and persistent hypophosphatemic rickets that responded poorly to standard phosphate and vitamin D treatment.

Two separate case reports of elderly men with novel FAM20C mutations have shown that even decades into adulthood, the gene change can present with low blood phosphate and soft bone tissue mixed with patches of dense bone. One report described a 61-year-old man with hypophosphatemic osteomalacia and bone sclerosis; another described a 72-year-old man with a similar pattern who also had spontaneous loss of blood supply to the knee. The same body of evidence shows that severity tracks with how much residual enzyme function the variants leave behind.

FGF23 and Phosphate Handling

FAM20C tags the hormone FGF23, which controls how much phosphate your kidneys hold onto. When FAM20C is impaired, FGF23 behaves abnormally, your kidneys spill phosphate into urine, and blood phosphate falls. This is the mechanism behind the bone softening seen across the Raine spectrum, and it is why FAM20C variants show up occasionally in workups for unexplained hereditary low phosphate.

A retrospective Norwegian study of 28 patients from 19 families with hereditary low phosphate found that the most common cause was PHEX-related X-linked hypophosphatemia, with FAM20C variants identified as a much rarer cause. A separate cohort investigating genetic causes of low phosphate reached the same conclusion: FAM20C is on the differential, but it is uncommon and typically presents with additional features beyond simple low phosphate.

Dental and Tooth Mineralization

Because FAM20C tags proteins that build dentin and enamel, people with damaging variants often have visible tooth changes. These include underdeveloped enamel, problems with the inner dentin layer, and abnormal tooth shape or eruption. Dental anomalies were a consistent feature across reported FAM20C cases, often appearing alongside the bone and phosphate findings.

Cerebral Calcifications

Calcium deposits inside the brain are a recurring feature of Raine syndrome. Multiple case reports describe these as visible on imaging, often present from birth in the severe form and detectable on prenatal ultrasound in some affected pregnancies. The mechanism connects back to FAM20C's role in regulating mineralization across tissues, where loss of the enzyme allows calcium to deposit in places it normally would not.

Cancer Associations in Tissue Studies

Research outside of inherited disease has looked at FAM20C expression in cancer tissue. A pan-cancer analysis reported that higher FAM20C expression in tumor tissue was associated with worse prognosis in bladder cancer, lower-grade glioma, and stomach adenocarcinoma. A separate genome-wide association study of adults with diffuse glioma (roughly 2,100 glioma cases analyzed against control groups) identified a variant near FAM20C linked to a specific glioma subtype (IDH-mutant, 1p/19q-codeleted, TERT-mutant).

These findings describe tumor tissue expression and genetic risk for specific cancer subtypes, not a screening role for the FAM20C genotype test in cancer prevention. The germline variants that cause Raine syndrome are distinct from the patterns of expression studied in tumor biology.

Your One-Time Result

Your FAM20C genotype does not change. The sequence you inherited at birth is the same sequence you will have at 80. A single, accurate test result is permanent, and there is no value in retesting the gene itself unless the original result is in doubt or a confirmatory method (such as targeted sequencing after a copy-number-based screen) is warranted.

The value of this test is in what it allows you to do once you know the result. If you carry a variant of interest, the action shifts to monitoring downstream phenotypes: serum phosphate, FGF23 if available, dental exams, bone imaging when clinically indicated, and conversations with family members about their own risk. These are the numbers worth tracking over time, not the genotype itself.

Decision Pathway for an Unexpected Result

A positive or uncertain FAM20C finding should prompt several next steps. First, consider a confirmatory test by a different method if the original assay was a panel or chip-based screen, because single-exon deletions in FAM20C have been missed by these methods. A preconception study reported a known pathogenic FAM20C exon deletion that was not detected by a clinical exome panel and would have required genome sequencing with copy-number analysis to find.

Second, order companion tests that reflect the downstream biology: serum phosphate, calcium, alkaline phosphatase, intact FGF23 if available, and a dental and skeletal assessment. Third, involve a genetic counselor or a specialist in bone and mineral disorders, especially if you are planning a pregnancy or have other family members at potential risk. Fourth, discuss the result with biological relatives. Raine syndrome is recessive, meaning carriers usually have no symptoms but can pass a damaged copy to children.

When Results Can Be Misleading

Genetic tests have specific failure modes worth knowing about. Variant panel coverage matters most: the assay only detects the specific variants it is designed to detect, and a negative result does not rule out other rare changes in the FAM20C gene. Single-exon deletions are a known blind spot for some panel-based methods.

• Panel coverage limits: the test detects specific variants and may miss large deletions, rare mutations, or changes outside the targeted regions of the FAM20C gene
• Ethnic-specific differences: some variants are more common in certain ancestries, so the clinical meaning of a result depends on your ancestral background
• Variants of uncertain significance: an unexpected change may be reported with unclear meaning, requiring further investigation or follow-up over time
• Direct-to-consumer differences: consumer genetics services may not test the same regions as clinical-grade panels, so results from those services should not be used as a final answer